PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32967924-0	2020	Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.	mgc018	27-33	CD276 molecule	Homo sapiens	89-94	
32967924-4	2020	In this article, we report the preclinical development of MGC018, an antibody-drug conjugate targeted against B7-H3.	mgc018	58-64	CD276 molecule	Homo sapiens	110-115	
32967924-5	2020	MGC018 is comprised of the cleavable linker-duocarmycin payload, valine-citrulline-seco duocarmycin hydroxybenzamide azaindole (vc-seco-DUBA), conjugated to an anti-B7-H3 humanized IgG1/kappa monoclonal antibody through reduced interchain disulfides, with an average drug-to-antibody ratio of ~2.7.	mgc018	0-6	CD276 molecule	Homo sapiens	165-170	
32967924-6	2020	MGC018 exhibited cytotoxicity toward B7-H3-positive human tumor cell lines, and exhibited bystander killing of target-negative tumor cells when co-cultured with B7-H3-positive tumor cells.	mgc018	0-6	CD276 molecule	Homo sapiens	37-42	
32967924-6	2020	MGC018 exhibited cytotoxicity toward B7-H3-positive human tumor cell lines, and exhibited bystander killing of target-negative tumor cells when co-cultured with B7-H3-positive tumor cells.	mgc018	0-6	CD276 molecule	Homo sapiens	161-166